IFG Advisory LLC Cuts Position in Novartis AG (NYSE:NVS)

IFG Advisory LLC lessened its position in shares of Novartis AG (NYSE:NVSFree Report) by 26.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,369 shares of the company’s stock after selling 1,192 shares during the quarter. IFG Advisory LLC’s holdings in Novartis were worth $340,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Syon Capital LLC bought a new stake in shares of Novartis in the 3rd quarter valued at approximately $6,568,000. Mather Group LLC. lifted its stake in shares of Novartis by 8.1% in the 3rd quarter. Mather Group LLC. now owns 7,763 shares of the company’s stock valued at $791,000 after purchasing an additional 580 shares during the last quarter. Global Retirement Partners LLC lifted its stake in shares of Novartis by 3.4% in the 3rd quarter. Global Retirement Partners LLC now owns 4,544 shares of the company’s stock valued at $437,000 after purchasing an additional 150 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of Novartis by 11.6% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 161,871 shares of the company’s stock valued at $16,488,000 after purchasing an additional 16,882 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Novartis by 1.4% in the 3rd quarter. LPL Financial LLC now owns 330,042 shares of the company’s stock valued at $33,618,000 after purchasing an additional 4,510 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Novartis Trading Up 0.9 %

Shares of NYSE NVS opened at $96.73 on Friday. The company has a quick ratio of 0.93, a current ratio of 1.15 and a debt-to-equity ratio of 0.39. The business has a fifty day simple moving average of $101.54 and a two-hundred day simple moving average of $99.75. The firm has a market cap of $205.03 billion, a PE ratio of 13.47, a price-to-earnings-growth ratio of 1.50 and a beta of 0.54. Novartis AG has a twelve month low of $89.81 and a twelve month high of $108.78.

Novartis (NYSE:NVSGet Free Report) last issued its earnings results on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The firm had revenue of $11.42 billion for the quarter, compared to the consensus estimate of $11.69 billion. Novartis had a net margin of 29.83% and a return on equity of 29.90%. During the same period last year, the firm earned $1.51 earnings per share. Analysts expect that Novartis AG will post 7.17 earnings per share for the current fiscal year.

Novartis Increases Dividend

The company also recently announced an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were given a dividend of $3.7772 per share. The ex-dividend date was Thursday, March 7th. This is a positive change from Novartis’s previous annual dividend of $3.47. This represents a yield of 3.1%. Novartis’s payout ratio is 34.26%.

Analyst Ratings Changes

NVS has been the subject of several analyst reports. HSBC lowered Novartis from a “buy” rating to a “hold” rating in a research note on Monday, December 18th. BMO Capital Markets initiated coverage on Novartis in a report on Friday, February 23rd. They set a “market perform” rating and a $114.00 price objective for the company. Morgan Stanley initiated coverage on Novartis in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price objective for the company. Finally, StockNews.com initiated coverage on Novartis in a report on Wednesday, December 6th. They set a “strong-buy” rating for the company. Three analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.33.

Check Out Our Latest Analysis on Novartis

About Novartis

(Free Report)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Recommended Stories

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.